These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 7538981)

  • 1. Relationship between histologic grading and serum prostate specific antigen in prostatic carcinoma.
    Lekili M; Zengin M; Postaci H; Ayder AR
    Int Urol Nephrol; 1994; 26(6):665-8. PubMed ID: 7538981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
    Blackwell KL; Bostwick DG; Myers RP; Zincke H; Oesterling JE
    J Urol; 1994 Jun; 151(6):1565-70. PubMed ID: 7514689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of modified Gleason grading of prostate carcinoma with age, serum prostate specific antigen and tumor extent in needle biopsy specimens.
    Helpap B; Egevad L
    Anal Quant Cytol Histol; 2008 Jun; 30(3):133-8. PubMed ID: 18630837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage.
    Grasso YZ; Gupta MK; Levin HS; Zippe CD; Klein EA
    Cancer Res; 1998 Apr; 58(7):1456-9. PubMed ID: 9537248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum prostate-specific antigen and the biologic progression of prostate cancer.
    Kabalin JN; McNeal JE; Johnstone IM; Stamey TA
    Urology; 1995 Jul; 46(1):65-70. PubMed ID: 7541589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
    Gettman MT; Pacelli A; Slezak J; Bergstralh EJ; Blute M; Zincke H; Bostwick DG
    Urology; 1999 Sep; 54(3):479-85. PubMed ID: 10475358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy.
    Lankford SP; Pollack A; Zagars GK
    Int J Radiat Oncol Biol Phys; 1997 May; 38(2):327-33. PubMed ID: 9226319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of serum prostate-specific antigen levels with the results of the prostate needle biopsy.
    Janbaziroudsari H; Mirzaei A; Maleki N
    Bull Cancer; 2016 Sep; 103(9):730-4. PubMed ID: 27345449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prostate cancer histoseminar: Update of the 2016 WHO classification - case No. 8: Acinar prostatic adenocarcinoma, Gleason score 6 (3+3)].
    Ferlicot S
    Ann Pathol; 2017 Jun; 37(3):259-263. PubMed ID: 28522121
    [No Abstract]   [Full Text] [Related]  

  • 10. Correlation of Gleason scores between needle-core biopsy and radical prostatectomy specimens in patients with prostate cancer.
    Hsieh TF; Chang CH; Chen WC; Chou CL; Chen CC; Wu HC
    J Chin Med Assoc; 2005 Apr; 68(4):167-71. PubMed ID: 15850066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Total PSA, PSA density and biopsy Gleason score in predicting the pathologic stage of prostate cancer].
    Liu S; Lü JJ; Fu Q; Zhang H; Gao DX; Liu Z
    Zhonghua Nan Ke Xue; 2010 May; 16(5):415-9. PubMed ID: 20684321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate adenocarcinoma using Gleason scores correlates with prostate-specific antigen and prostate acid phosphatase measurements.
    Shih WJ; Gross K; Mitchell B; Collins J; Wierzbinski B; Magoun S; Ryo UY
    J Natl Med Assoc; 1992 Dec; 84(12):1049-50. PubMed ID: 1284282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Needle biopsy findings in prostatic adenocarcinoma: experience at a tertiary care center in a developing country.
    Ahmad Z; Arshad H
    Ann Diagn Pathol; 2013 Jun; 17(3):235-8. PubMed ID: 23199761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
    Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
    Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified Gleason grading. An updated review.
    Helpap B; Egevad L
    Histol Histopathol; 2009 May; 24(5):661-6. PubMed ID: 19283673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of free PSA/total PSA ratio in therapeutic decisions in the case of a single positive biopsy of the prostate].
    Huyghe E; Soulie M; Tollon C; Escourrou G; Pontonnier F; Plante P
    Prog Urol; 1999 Apr; 9(2):281-7. PubMed ID: 10370952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
    Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
    J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
    Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
    Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gleason grading and prognostic factors in carcinoma of the prostate.
    Humphrey PA
    Mod Pathol; 2004 Mar; 17(3):292-306. PubMed ID: 14976540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.